Lesional and non-lesional skin gene-expression profiles from Phase-3 clinical trials of Brodalumab

ABSTRACT: IL-17 antagonists induce impressive clinical benefit in psoriasis, but it is unknown too what extent cellular and molecular characteristics of psoriasis are suppressed by a clinically relevant dose and schedule of any IL-17 antagonist. Examine the effects the IL-17A receptor antagonist brodalumab, on the clinical and molecular characteristics of psoriasis, including IL-17 dependent gene-sets.

ORGANISM(S): Homo sapiens

PROVIDER: GSE117468 | GEO | 2020/04/02

REPOSITORIES: GEO